American U.S. The Food and Drug Administration (FDA) has approved the use of a new anti-insomnia drug in adults. This is a lemborexant (lemborexant) - an antagonist of orexin receptors, which is a new class of drugs. The drug reportedly binds to two orexin receptors - OX1R and OX2R. According to Remedium, this medicine regulates the sleep and wake cycle, without affecting the ability to wake up from external stimuli. As shown by clinical trials involving 949 people 18-88 years old, lasting 12 months, the drug is effective and safe at a dosage of 5 and 10 milligrams.

Studies have shown that statistically significant improvement in the rates of falling asleep and the quality of sleep is observed against the background of therapy with Lemborexant. But this drug can also cause addiction, experts warn.